Group 1 - Kanglongda's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 4.83 million shares [1] - The company specializes in the research, production, and sales of special and ordinary labor protection gloves [1] Group 2 - Haizheng Pharmaceutical's subsidiary plans to collaborate with East China Institute on a biological method for synthesizing heparin, with a project contract amount not exceeding 120 million yuan [2] - The company focuses on the research, production, and sales of chemical raw materials and formulations [3] Group 3 - Tianyin Holdings received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [4] - The company is engaged in the sales of smart terminals, e-commerce, lottery, mobile resale, and mobile internet businesses [4] Group 4 - Shanghai Yashi plans to use up to 200 million yuan of temporarily idle raised funds for cash management in high-security, liquid deposit products [5] - The company specializes in supply chain logistics and execution trade [6] Group 5 - Parker New Materials intends to use 130 million yuan of idle raised funds to purchase structured deposits with expected annual yields between 0.59% and 2.9001% [7] - The company focuses on the research, production, and sales of various types of ring forgings, free forgings, and die forgings [7] Group 6 - Huayang New Materials appointed Jing Hongsheng as the new general manager [8] Group 7 - Liyuan Technology's shareholder plans to reduce holdings by up to 2.03% of the company's shares, totaling no more than 3.04 million shares [9] - The company specializes in the research, design, and integration of environmental water treatment systems and hydrogen fuel cell engine systems [9] Group 8 - Shengnuo Biopharmaceutical's subsidiary received approval for the listing application of Visepegenatide raw materials, a GLP-1 receptor agonist for treating type 2 diabetes and obesity [10][11] - The company focuses on the research, production, and sales of peptide raw materials and formulations [10] Group 9 - Puluo Pharmaceutical plans to repurchase shares worth between 180 million and 360 million yuan, with a maximum price of 23 yuan per share [12] - The company specializes in the research, production, and sales of raw material intermediates and innovative drugs [12] Group 10 - Dongfang Electric's subsidiary plans to establish a joint venture with Anhui Waneng Energy, with a registered capital of approximately 1.857 billion yuan [13] - The company is involved in the development, design, manufacturing, and sales of advanced power generation equipment [13] Group 11 - Hefei China announced that its stock will resume trading on November 20 after completing a review of abnormal trading fluctuations [14] - The company focuses on international trade and after-sales services related to in vitro diagnostic medical devices [14] Group 12 - Dafeng Industrial won a bid for the stage equipment project of the Shenzhen International Performing Arts Center, with a contract amount of 165 million yuan [15] - The company specializes in cultural sports equipment, digital art technology, and operation services [15] Group 13 - Baiyunshan's subsidiary received a drug registration certificate for An Gong Niu Huang Wan in Vietnam [16] - The company is engaged in the research, manufacturing, and sales of traditional Chinese and Western medicines [16] Group 14 - Neusoft Group received a notification to supply intelligent cockpit domain controllers for multiple models from a well-known domestic automobile manufacturer, with an estimated total amount of about 4.2 billion yuan [17] - The company focuses on providing industry solutions and software products [17] Group 15 - Huayu Pharmaceutical's product received overseas marketing approval [18] - The company specializes in the research, production, and sales of innovative and high-quality generic drugs in the oncology field [18] Group 16 - Yao Pi Glass received approval from the CSRC for its stock issuance to specific investors [19] - The company specializes in the production and sales of float glass and processed glass [19] Group 17 - Guangyu Yuan's vice president Wang Junbo resigned due to work adjustments [20] - The company focuses on the production and sales of traditional Chinese medicine products [20] Group 18 - Biyi Co. received approval from the CSRC for its stock issuance to specific investors [21] - The company specializes in the design, manufacturing, and sales of smart small household appliances [21] Group 19 - Sunshine Nuohe's application for acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. through share issuance and convertible bonds has been accepted by the Shanghai Stock Exchange [22] - The company provides comprehensive drug research and development services for domestic pharmaceutical enterprises and research institutions [22] Group 20 - Longxin General plans to increase capital in its wholly-owned subsidiary by no more than 1.65 billion yuan [23] - The company specializes in the research, production, and sales of motorcycles and engines [23] Group 21 - Jiekang Equipment received a corrective order from the Tianjin Securities Regulatory Bureau due to internal control deficiencies [24] - The company specializes in the research, production, and sales of nuclear biochemical safety equipment [24] Group 22 - Wantong Technology plans to raise no more than 920 million yuan through a private placement to supplement working capital [25] - The company focuses on information technology services for highways and ports [25] Group 23 - Dongshan Precision has submitted an application for H-share listing to the Hong Kong Stock Exchange [26] - The company specializes in the research, production, and sales of electronic circuit products and precision components [26] Group 24 - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Kunming Medical Oncology Hospital [27] - The company specializes in water and heating valve fittings, tumor precision radiation therapy, and photovoltaic battery businesses [27] Group 25 - Aok Shares signed a strategic cooperation framework agreement with Suzhou Qitian New Materials Co., Ltd. [28] - The company focuses on the research and production of high-end new materials derived from ethylene oxide and ethylene [28] Group 26 - Hongquan Technology's shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 299,440 shares [29] - The company specializes in the research, production, and sales of intelligent connected products and software platform development [29] Group 27 - Shilong Industrial's controlling shareholder plans to reduce holdings by up to 3% of the company's shares, totaling no more than 7.2 million shares [30] - The company specializes in the research, production, and sales of chemical products [30] Group 28 - Tangrenshen decided to terminate the investment in the "Dongchong Phase III Pig Breeding Base Construction Project," reallocating the remaining funds of 78.9587 million yuan to supplement working capital [31] - The company specializes in the research, production, and sales of feed, pigs, meat products, and animal health products [31] Group 29 - Gaode Infrared's actual controller plans to reduce holdings by up to 3% of the company's shares, totaling no more than 12.8 million shares [32] - The company specializes in infrared focal plane detector chips and infrared thermal imaging systems [32] Group 30 - Kangyuan Pharmaceutical's actual controller recently increased holdings by 20,000 shares [33] - The company specializes in the research, production, and sales of pharmaceuticals [33] Group 31 - Haida Group plans to repurchase shares worth between 1 billion and 1.6 billion yuan, with a maximum price of 62.00 yuan per share [34] - The company provides overall solutions for animal husbandry [34] Group 32 - Qizhong Technology's 850 million yuan convertible bonds have been approved for listing [35] - The company specializes in advanced packaging and testing of integrated circuits [35] Group 33 - Dingyang Technology launched the new SNA5000B series vector network analyzer [36] - The company specializes in the research, production, and sales of general electronic testing and measuring instruments [36] Group 34 - Airo Energy plans to distribute a cash dividend of 0.9375 yuan per share to all shareholders [37] - The company specializes in photovoltaic energy storage systems and products [37] Group 35 - Hechuan Technology's actual controller and some directors plan to reduce holdings by up to 6% of the company's shares [38] - The company specializes in the research, production, and sales of industrial automation products [38] Group 36 - China First Heavy Industries' chairman was arrested for suspected bribery [39] - The company specializes in heavy machinery manufacturing for various industries [39] Group 37 - Lianhuan Pharmaceutical plans to invest 15 million yuan in joint research with Nanjing University for anti-thrombotic small nucleic acid drugs [40] - The company specializes in the manufacturing and sales of chemical raw materials [40] Group 38 - Anxu Biotech's shareholder plans to reduce holdings by up to 0.94% of the company's shares, totaling no more than 120,000 shares [41] - The company specializes in the research, production, and sales of POCT reagents and instruments [41] Group 39 - Yaxiang Integration's shareholder reduced holdings by 130,000 shares [42] - The company specializes in providing cleanroom engineering and related services for high-tech electronic industries [42] Group 40 - Zhongwen Media plans to use up to 9.5 billion yuan of idle funds to purchase financial products [43] - The company specializes in traditional publishing and various new media businesses [43]

Group 1 - The core point of the article is that Haizheng Pharmaceutical announced the establishment of a wholly-owned subsidiary in Jiaojiang to advance its pet prescription food project [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical production accounts for 58.46%, drug sales for 39.29%, other industries for 1.94%, other businesses for 0.23%, and CMO/CDMO/CRO business for 0.08% [1] - As of the report, Haizheng Pharmaceutical has a market capitalization of 12.8 billion yuan [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-70 号 浙江海正药业股份有限公司 第十届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）第十届董事会第九次会 议于 2025 年 11 月 19 日在台州总部公司会议室以现场加通讯方式召开。应参加 会议董事 9 人，亲自参加会议董事 9 人，公司高级管理人员列席了会议。本次会 议的召开程序符合《公司法》和《公司章程》的规定，会议合法有效。本次会议 由公司董事长肖卫红先生主持，经与会董事认真讨论研究，会议审议并通过了如 下决议： 一、关于浙江海正动物保健品有限公司投资设立椒江全资子公司并推进宠 物处方粮项目的议案； 为把握宠物大健康产业发展机遇，依托公司及控股子公司浙江海正动物保 健品有限公司（以下简称"海正动保"）在宠物药品领域的资源积累，推进业务 向宠物营养健康领域延伸，董事会同意海正动保使用自有资金 1 亿元，在台州市 椒江区设立全资子公司并投资建设宠物处方粮项目。具体情况如下： （一 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) announced a collaboration with East China Synthetic Biology Industry Technology Research Institute to develop and industrialize bioengineered heparin drugs using synthetic biology, with a project contract amount not exceeding 120 million yuan [1] Group 1 - The collaboration aims to enhance the company's product coverage in the field of synthetic biology [1] - The project is expected to promote the development of the synthetic biology industry [1] - The total contract amount for the project is capped at 120 million yuan [1]

Core Viewpoint - Haizheng Pharmaceutical (600267) announced the establishment of a wholly-owned subsidiary, Haizheng Animal Health, to invest in a pet prescription food project in Taizhou, Zhejiang Province, with a total investment of 200 million yuan [1] Company Summary - The company plans to use its own funds of 100 million yuan for the project [1] - The project will be implemented in two phases, with the first phase having a construction period of 24 months [1] - Upon reaching full production capacity, the project is expected to add an annual production capacity of 10,000 tons of pet prescription food [1] Industry Summary - The investment in the pet prescription food sector indicates a strategic move to tap into the growing demand for specialized pet nutrition [1] - The establishment of the subsidiary and the project aligns with industry trends focusing on health and wellness in pet care [1]

（记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：能否介绍下海正药业的CMO业务？公司是否把这业务 当作核心业务之一？公司和哪些药业有合作？ 海正药业（600267.SH）11月14日在投资者互动平台表示，尊敬的投资者您好！公司CMO业务目前主要 由台州和富阳基地承接，具体业务受客户端制剂需求影响，存在一定的不确定性，但总体保持一个健康 稳定的发展态势。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025年11月12日 (二)股东会召开的地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路46号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 注：截止本次股东会股权登记日，公司总股本为1,198,848,196股，其中公司回购专用账户的股份数量为 36,291,300股，该等回购的股份不享有表决权，故本次股东会享有表决权的股份总数为1,162,556,896 股。 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 公司2025年第二次临时股东会采用现场投票和网络投票相结合的表决方式审议有关议案，本次股东会由 浙江海正药业股份有限公司董事会召集，董事长肖卫红先生主持。会议召集、召开及表决方式符合《公 司法》等有关法律法规和《公司章程》的规定。 2、公司董事会秘书沈锡飞先生出席本次会议；部分高管列席本次会议。 二、议案审议情况 ...

北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2025 年第二次临时股东会的 康达(杭州)股会字【2025】第 0030 号 二〇二五年十一月 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 北京康达（杭州）律师事务所 海正药业 2025 年第二次临时股东会法律意见书 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2025 年第二次临时股东会的法律意见书 康达(杭州)股会字【2025】第 0030 号 致：浙江海正药业股份有限公司 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正药业股份有限 公司（下称"海正药业"或"公司"）委托，指派本所律师出席公司 2025 年第 ...

证券代码：600267 证券简称：海正药业 公告编号：临2025-69号 浙江海正药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 12 日 (二)股东会召开的地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙 路 46 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 552 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 493,903,134 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 42.4842 | 注：截止本次股东会股权登记日，公司总股本为 1,198,848,196 股，其中公司回购专用账户 的股份数量为 36,291,300 股，该等回购的股份不享有表决权，故本次股东会享有表决权的 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has approved the public transfer of 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., to optimize its business structure and focus on core advantages in the pharmaceutical industry [1][2] Group 1 - The board of directors has confirmed that the announcement contains no false records, misleading statements, or significant omissions, and they bear legal responsibility for its authenticity, accuracy, and completeness [1] - The equity of Zhejiang Pharmaceutical Industry Co., Ltd. is assessed at 392.2339 million yuan, with a proposed public listing price of 430 million yuan [1] - The public transfer application for the equity was submitted to Taizhou Property Rights Exchange on November 10, 2025, with the listing period from November 11 to December 8, 2025 [2] Group 2 - The company has provided details for the public transfer on the websites of Zhejiang Property Rights Exchange and Taizhou Property Rights Exchange, and investors can inquire further by phone [2] - There is a potential risk of unsuccessful delisting for the public transfer of the equity, and the company will fulfill its information disclosure obligations based on the progress of this matter [2] - The designated media for information disclosure includes China Securities Journal, Shanghai Securities Journal, Securities Times, and the Shanghai Stock Exchange website [2]